Reference
Food and Drug Administration (FDA). FDA alerts patients and health care professionals about clinical trial results showing an increased risk of death associated with Pepaxto (melphalan flufenamide). Internet Document : 28 Jul 2021. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-about-clinical-trial-results-showing-increased
Rights and permissions
About this article
Cite this article
Increased risk of death with melphalan flufenamide. Reactions Weekly 1868, 1 (2021). https://doi.org/10.1007/s40278-021-00458-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-00458-9